This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Start With Proven First-line Efficacy1-3
Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.3
ESMO clinical practice guidelines for Stage IV lung carcinoma with EGFR-activating mutation4
ESMO Clinical Practice Guidelines recommend DACOPLICE® as one of the first options for Stage IV lung carcinoma with EGFR-activating mutation.4,5
ESMO treatment algorithm4
Adapted from Planchard D, et al. 2018.
DACOPLICE® may preserve targeted treatment options for tumours that develop the T790M resistance mutation.6,7
*MCBS score for the combination of bevacizumab with gefitinib or erlotinib.4
†Not approved by the EMA.4
The levels of evidence and grades of recommendation are shown from the ESMO guidelines.4 The ESMO-MCBS is a standardised, validated approach that helps to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer treatments. The scale is graded 1-5 (Grades 4 and 5 represent a high level of proven clinical benefit).8 Version 1.1 of the ESMO-MCBS has been used here.4
CfDNA, cell-free deoxyribonucleic acid; CHT, chemotherapy; CI, confidence interval; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; ESMO, European Society for Medical Oncology; HER, human epidermal growth factor receptor; HR, hazard ratio; IRC, independent radiological central; MCBS, Magnitude of Clinical Benefit Scale; PS, performance status; RT, radiotherapy; TKI, tyrosine kinase inhibitor.
References:
Please click the Prescribing Information link to view the safety and adverse events information of DACOPLICE®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-DAC-IND-0147 June 2022
DACOPLICE® is a second-generation EGFR TKI
Learn more
Start with proven first-line efficacy
Learn more
First-line use of DACOPLICE® was studied in a Phase III, head-to-head trial with gefitinib
Review efficacy profile
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022